Solid tumors
Conditions
Interventions
mtDNA high mutation burden group/mtDNA low mutation burden group/healthy T cell donor group/mitochondrial replacement intervention group:None
Sponsors
The University of Hongkong - Shenzhen Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Clinical blood samples that meet the following criteria may be included in this study: 1. Age range: 18-70 years old, sample providers need to sign an informed consent form. 2. There is no restriction on gender. 3. Sample source: From the remaining blood samples after routine clinical testing, no additional blood draw is required. 4. Mainly from: tumor patients (mainly solid tumors, used to evaluate the immune function of mtDNA mutations on T cells can affect hematologic tumors). 5. Sample quality requirements: a. Remaining blood sample volume>=2ml (suitable for cell assays and DNA extraction). b. No significant hemolysis, coagulation, or contamination of the blood sample. 6. Patients with a deleterious mutation rate of mitochondrial function in T cells of cancer patients with a > 60% were included in the mitochondrial replacement intervention group. 7. Healthy individual T cells without obvious mutations in mtDNA can be used as mitochondrial donors. 8. Ethical: The study participant agrees to use the remaining blood samples after their routine testing and signs the relevant documents.
Exclusion criteria
Exclusion criteria: Blood samples that meet any of the following will be excluded: 1. Not meeting age requirements: Provider age 70 years. 2. Originated in pregnant or lactating women (to reduce potential effects). 3. Unqualified sample quality: a. Hemolyzed, coagulated, microbial contaminated samples. b. Insufficient sample size (<2ml to meet DNA extraction and T cell analysis needs). 4. The clinical background does not meet the requirements: a. Provider has a confirmed autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis). b. Recent treatment with radiotherapy, chemotherapy, or immunosuppressive therapy (within 3 months). c. Provider has a serious infectious disease (e.g., tuberculosis, hepatitis B/C, AIDS). d. The provider has a hematologic disorder (e.g., leukemia, lymphoma). 5. Study participants have other immune system disorders (e.g., autoimmune diseases) that may affect T cell function. 6. Study participant has recently received immunosuppressive therapy (e.g., CAR-T therapy, chemoradiotherapy). 7. Impaired mitochondrial function of donor T cells or known pathological mutations. 8. The sample source does not meet the ethical requirements: the subject has not signed the informed consent form or explicitly refuses to use their clinical remaining blood sample in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cell Killing Rate (Flow Cytometry/LDH Release/51Cr Release);Metabolic status (oxygen consumption rate OCR, glycolytic ECAR);T cell proliferative capacity (CFSE dilution); | — |
Countries
China
Contacts
Public ContactMa Wenting
The University of Hongkong - Shenzhen Hospital
Outcome results
None listed